Concepts for banking tissue in urologic oncology - The International Bladder Cancer Bank

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 413-415

  Goebell, Peter J ^a,b   Groshen, Susan ^a   Schmitz Dräger, Bernd J ^c   Sylvester, Richard ^d   Kogevinas, Manolis ^e   Malats, Núria ^e   Sauter, Guido ^f   Grossman, H Barton ^g   Dinney, Colin P N ^g   Waldman, Fred ^h   Cote, Richard J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c EuromedClinic ^*  (Germany)

^d Head Meta Analysis Unit   (Belgium)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

BLADDER CANCER; BLADDER CANCER BANK; DISEASE MARKER; EVALUATION; GENOMICS; HEALTH CARE FACILITY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INTERNATIONAL COOPERATION; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; STANDARDIZATION;

HUMANS; MEDICAL ONCOLOGY; PROGNOSIS; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGY; WORLD HEALTH;

EID: 19944428325     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Malkin A. Tumor markers. In: Tannock IF, Hill RP, editors. The basic science of oncology. 2nd ed. New York: McGraw-Hill; 1992.
2. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992;19:429-33.
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
4. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
5. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-4.
6. Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 1999;5:2-15.
7. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979;76:2420-4.
8. Melero JA, Stitt DT, Mangel WF, Carroll RB. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology 1979;93:466-80.
9. Oka K, Ishikawa J, Bruner JM, Takahashi R, Saya H. Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction. Mol Carcinog 1991;4:10-3.
10. Borland RN, Brendler CB, Isaacs WB. Molecular biology of bladder cancer. Hematol Oncol Clin North Am 1992;6:31-9.
11. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
12. Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50:7081-3.
13. Llopis J, Alcaraz A, Ribal MJ, et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644-53.
14. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
15. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997;385:123-5.
16. Esrig D, Spruck CH III, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
17. Cordon-Cardo C, Dalbagni G, Saez GT, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53.
18. Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer: a new toy for urologic scientists? Eur Urol 2000;38:691-700.
19. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000;6:1854-64.
20. Grossman HB. The first and second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urol Oncol 2000;5:183-4.
21. Malone T, Catalano PJ, O'Dwyer PJ, Giantonio B. High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience. J Natl Cancer Inst 2002;94:769-71.
22. Schilsky RL, Dressler LM, Bucci D, et al. Cooperative group tissue banks as research resources: the Cancer and Leukemia Group B tissue repositories. Clin Cancer Res 2002;8:943-8.
23. Goebell PJ, Groshen S, Schmitz-Dräger BJ, et al. The International Bladder Cancer Bank-proposal for a new study concept. Urol Oncol 2004;22:277-84.
24. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.